The Alzheimer's Association International Conference (AAIC) 2026 in Los Angeles served as a critical venue for industry engagement in Alzheimer's disease research. Satellite symposia, organized by pharmaceutical companies, biotechnology firms, and research organizations, provided in-depth coverage of pipeline programs, clinical trial results, and therapeutic strategies that complement the scientific sessions of the main conference[@aaic2026].
Overview
Mermaid diagram (expand to render)
The satellite symposia program at AAIC 2026 represents a vital component of the conference, providing companies with opportunities to present detailed data, engage with key opinion leaders, and discuss their therapeutic pipelines with the research community. These sessions complement the abstract-driven presentations of the main sessions by offering more comprehensive updates on specific therapeutic approaches and corporate research strategies.
The 2026 satellite symposia reflected the evolving Alzheimer's disease therapeutic landscape, which has been transformed by the approval of disease-modifying anti-amyloid antibodies and the continued advancement of tau-targeted, neuroprotective, and precision medicine approaches. The field has moved from a period of repeated clinical trial failures to one of unprecedented optimism, with multiple agents demonstrating amyloid clearance and potential clinical benefit["@scheltens2023"][@cummings2024].
Major Pharmaceutical Partners
Biogen
Biogen's Alzheimer's franchise has evolved significantly following the conditional approval and subsequent withdrawal of aducanumab (Aduhelm). The company continues to pursue next-generation approaches targeting multiple mechanisms:
- Anti-amyloid portfolio: Development of next-generation monoclonal antibodies with improved efficacy and safety profiles
- BACE inhibitors: Early intervention strategies targeting beta-secretase
- Tau programs: Partnerships for anti-tau therapeutic development
- Neuroprotection: Small molecule approaches for synapse preservation
The company's satellite symposium at AAIC 2026 focused on their strategic approach to early intervention, including data from ongoing Phase 2 studies evaluating novel mechanisms beyond amyloid targeting[@sevigny2016].
Eisai
Eisai, in partnership with Biogen, brought lecanemab (Leqembi) to market as the first fully approved anti-amyloid antibody demonstrating both amyloid clearance and clinical benefit. The company's satellite symposium provided:
- Real-world effectiveness data: Post-approval clinical experience with lecanemab
- Clarity ARIA management: Optimized protocols for amyloid-related imaging abnormalities
- Biomarker correlatives: CSF and blood-based marker changes accompanying treatment
- Combination strategies: Plans for combination therapy approaches
Lecanemab received full FDA approval in July 2024 following the Phase 3 CLARITY-AD trial demonstrating 27% slowing of clinical decline at 18 months, with robust amyloid plaque reduction and favorable biomarker changes[@vanDyck2023].
Eli Lilly
Eli Lilly's donanemab (Kisunla) achieved FDA approval as the second anti-amyloid antibody demonstrating disease modification in early Alzheimer's disease. The company's satellite symposium featured:
- TRAILBLAZER-ALZ 2 results: Full Phase 3 data in low/medium and high tau populations
- Remternetug: Next-generation anti-amyloid antibody in Phase 3
- Tau imaging programs: Development of tau PET endpoints for clinical trials
- Precision medicine approach: Targeting patients based on tau pathology burden
Donanemab demonstrated 35% slowing of decline in patients with low/medium tau and 22% in the overall population at 18 months, with the unique feature of allowing potential treatment discontinuation after amyloid clearance[@sims2023].
Roche/Genentech
Roche's comprehensive Alzheimer's program spans multiple mechanisms:
- Gantenerumab (RG1450): Anti-amyloid antibody completing development program
- Tau programs: Anti-tau antibodies in clinical development
- TREM2 modulation: Agonist antibodies targeting microglial activation
- Diagnostic partnerships: Collaboration on biomarker development
The Roche satellite symposium highlighted their TREM2 agonist program, which represents a novel approach to addressing neuroinflammation, a key contributor to Alzheimer's disease pathogenesis[@wang2024].
Johnson & Johnson
Johnson & Johnson's neuroscience pipeline includes:
- Amyloid-targeting programs: Early-stage anti-amyloid development
- Tau programs: Anti-tau antibody development
- Genetic subtype approaches: Precision medicine for LRRK2 and other genetic variants
- Diagnostic development: Biomarker strategies for patient selection
Biotechnology Partners
AC Immune
AC Immune has established itself as a leader in immunotherapy approaches for neurodegenerative diseases:
- ACI-35: Phospho-tau active vaccination program
- Anti-tau antibodies: Monoclonal antibodies targeting pathological tau
- Alpha-synuclein programs: Immunotherapy for Lewy body diseases
- Small molecule inhibitors: Aggregation inhibitors for multiple proteins
The company's satellite symposium detailed the ACI-35 vaccination program, which aims to generate antibodies against phosphorylated tau, potentially offering advantages over passive immunization approaches[@tahami-monfared2024].
Prothelia
Prothelia focuses on prion protein and protein misfolding diseases:
- Anti-PrP antibodies: Targeting prion protein in Alzheimer's and prion disease
- Oligomer-targeted approaches: Focusing on toxic soluble oligomers
- Combination strategies: Dual-targeting approaches
Cognition TherapeuticsCognition Therapeutics develops sigma-2 receptor modulators:
- CT1812 (Sореnemetostat): Sigma-2 receptor modulator in Phase 2
- Synaptic protection: Mechanisms targeting synapse degeneration
- Alzheimer's and Parkinson's programs: Pipeline across neurodegenerative diseases
Satellite Symposia Sessions
Morning Sessions
| Company | Topic | Highlights |
|---------|-------|------------|
| Eisai | Lecanemab Updates | Real-world efficacy data, ARIA management protocols, biomarker correlatives |
| Lilly | Anti-Tau Pipeline | Donanemab full results, remternetug Phase 3, tau PET endpoints |
| Biogen | Next-Gen Approaches | Novel mechanisms beyond amyloid, early intervention strategies |
| Roche | TREM2 Modulation | Agonist antibody data, microglial activation targeting |
| AC Immune | Vaccine Platforms | ACI-35 phospho-tau vaccine results, immunotherapy pipeline |
Afternoon Sessions
| Company | Topic | Highlights |
|---------|-------|------------|
| J&J | Genetic Subtypes | LRRK2 targeting, precision medicine approaches |
| Prothelia | Prion Protein | Oligomer-targeted therapies |
| Cognition | Sigma-2 Modulators | CT1812 Phase 2 results, synaptic protection |
| Diagnostics | Biomarker Platforms | Blood-based biomarker development, point-of-care testing |
Session Highlights
Anti-Amyloid Therapy Updates
The satellite symposia provided detailed updates on anti-amyloid therapeutic development:
Amyloid-Related Imaging Abnormalities (ARIA) Management
- Updated consensus guidelines for ARIA detection and management
- Monitoring protocols using MRI and clinical assessment
- Risk factors including APOE4 genotype, anticoagulation use
- Strategies for managing ARIA while maintaining therapeutic benefit[barakos2024]
Biomarker Correlates
- Amyloid PET standardized uptake value ratio (SUVr) changes
- CSF amyloid and tau biomarker shifts
- Blood-based biomarker changes (p-tau181, p-tau217)
- Correlation with clinical outcomes[hansson2024]
Treatment Optimization
- Dosing regimens for optimal amyloid clearance
- Treatment duration and potential for discontinuation after clearance
- Combination therapy approaches with other mechanisms
Tau-Targeting Therapies
Tau remains the second major therapeutic target in Alzheimer's disease:
Anti-Tau Antibodies
- Multiple antibodies in clinical development
- Target different epitopes and tau species
- PET imaging for target engagement and treatment response
Tau Aggregation Inhibitors
- Small molecules targeting tau aggregation
- Mechanisms of action and clinical development status
- Combination with anti-amyloid approaches[tahami-monfared2024]
Tau Vaccination
- Active immunization against pathological tau
- ACI-35 and similar programs
- Challenges with immune response and antibody generation
Neuroinflammation and Microglial Activation
The role of neuroinflammation in Alzheimer's pathogenesis has gained significant attention:
TREM2 Targeting
- TREM2 agonist antibodies
- TREM2 genetic variants and their effects on disease risk
- Microglial modulation strategies[wang2024]
Complement System
- Complement inhibitors for neuroinflammation
- C1q targeting approaches
- Synaptic protection mechanisms
Microglial Activation
- Phenotypic changes in Alzheimer's disease
- Therapeutic targeting of specific microglial states
- Biomarkers of neuroinflammation[bassetti2024]
Investigator-Initiated Studies
Industry partnerships with academic researchers support:
- Biomarker validation studies: Independent validation of biomarker assays
- Real-world evidence collection: Clinical outcomes in diverse populations
- Subgroup analyses: Understanding treatment effects across patient populations
- Long-term follow-up: Extended observation of treated patients
Data Sharing Initiatives
Collaborative approaches to advancing research:
- Public-private partnerships: Coalition for Alzheimer's drug discovery
- Cross-company data harmonization: Standardized data formats and endpoints
- Open science frameworks: Pre-competitive collaboration on basic mechanisms
- Trial data sharing: Access to clinical trial datasets for secondary analyses
Research Grants and Fellowships
Alzheimer's Association Grants
The Alzheimer's Association supports research through:
- AAIC Awards: Young investigator awards presented at the conference
- Part the Cloud: Funding for translational research
- Strategic Fund: Priority research areas including biomarkers and precision medicine
- International Collaborations: Global research partnerships
Industry Fellowships
Pharmaceutical and biotechnology companies provide:
- Postdoctoral fellowships: Training the next generation of researchers
- Clinical research training: Development of clinical trial expertise
- Technology development grants: Supporting innovation in diagnostics and digital health
Exhibit Hall Highlights
Booth Presentations
Demo Theaters
- Product information sessions
- Device demonstrations
- Technology tutorials
Research Posters
- Company-sponsored scientific presentations
- Late-breaking research
- Pipeline updates
Networking Lounges
- Partnering opportunities
- Academic collaborations
- Clinical trial discussions
Technology Showcase
Diagnostic Platforms
- Blood-based biomarker testing systems
- Point-of-care testing devices
- CSF assay automation
Digital Health
- Wearable devices for cognitive monitoring
- Remote patient monitoring platforms
- Telehealth solutions
AI/ML Tools
- Data analysis platforms
- Clinical trial optimization
- Patient stratification algorithms
Therapeutic Pipeline Overview
The satellite symposia reflected the robust Alzheimer's disease therapeutic pipeline[cummings2024]:
Phase 3 Programs
- Multiple anti-amyloid antibodies in late-stage development
- Tau-targeted agents advancing
- Neuroprotective and disease-modifying approaches
Phase 2 Programs
- Novel mechanisms including TREM2 modulators
- Anti-inflammatory approaches
- Metabolic and vascular targeting
Phase 1 Programs
- Gene therapy approaches
- Cell-based therapies
- Novel small molecule mechanisms
Key Takeaways
Pharma engagement remains strong in Alzheimer's research despite past clinical trial challenges, with multiple major pharmaceutical companies maintaining robust pipelines
Anti-amyloid therapies have transformed the field, with lecanemab and donanemab establishing disease modification as achievable, while next-generation programs aim to improve on current results
Tau targeting is accelerating, with multiple programs in clinical development and tau PET enabling patient selection and treatment response monitoring
Neuroinflammation represents the next frontier, with TREM2 and complement modulators offering novel mechanisms beyond amyloid and tau
Precision medicine approaches are emerging, including genetic subtyping, biomarker-based patient selection, and combination therapy strategies
Biomarker-driven treatment is becoming reality, with blood-based biomarkers enabling broader screening and treatment decisions
Collaboration models are evolving, with increased data sharing, public-private partnerships, and open science approachesRelated Pages
- [AAIC 2026 Conference](/events/aaic-2026)](/events)
- [AAIC 2026 Company Presentations](/events/aaic-2026-company-presentations)](/events)
- [AAIC 2026 Emerging Therapeutic Targets](/events/aaic-2026-emerging-therapeutic-targets)](/events)
- [AAIC 2026 Clinical Trials](/events/aaic-2026-clinical-trials)](/clinical-trials)
- [AAIC 2026 Posters and Abstracts](/events/aaic-2026-posters-abstracts)](/events)
- [Lecanemab](/therapeutics/lecanemab)](/therapeutics)
- [Donanemab](/therapeutics/donanemab)](/therapeutics)
- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)](/therapeutics)
- [Tau Immunotherapy](/therapeutics/tau-immunotherapy)](/therapeutics)
- [TREM2](/proteins/trem2)
References
[AAIC 2026 Conference](https://aaic.alz.org)
[Scheltens P, et al., Alzheimer's disease: The landscape is evolving. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00740-7)
[Cummings JL, et al., Alzheimer's disease drug development pipeline: 2024. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13956)
[van Dyck CH, et al., Lecanemab in early Alzheimer's disease. N Engl J Med. 2023 (2023)](https://doi.org/10.1056/NEJMoa2303070)
[Sims JR, et al., Donanemab in early Alzheimer's disease. N Engl J Med. 2023 (2023)](https://doi.org/10.1056/NEJMoa2304130)
[Barakos J, et al., Amyloid-related imaging abnormalities in anti-amyloid therapy. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00791-8)
[Tahami-Monfared AA, et al., Tau-targeting therapies for Alzheimer's disease: Current landscape. Nat Rev Drug Discov. 2024 (2024)](https://doi.org/10.1038/s41573-024-00901-7)
[Wang Y, et al., TREM2 biology and therapeutic targeting in Alzheimer's disease. Nat Rev Neurosci. 2024 (2024)](https://doi.org/10.1038/s41583-024-00800-3)
[Hansson O, et al., Blood-based biomarkers for Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00775-7)
[Gauthier S, et al., New directions in Alzheimer's disease diagnosis and treatment. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00701-3)